Journal article

Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Reisa A Sperling, Paul S Aisen, Laurel A Beckett, David A Bennett, Suzanne Craft, Anne M Fagan, Takeshi Iwatsubo, Clifford R Jack, Jeffrey Kaye, Thomas J Montine, Denise C Park, Eric M Reiman, Christopher C Rowe, Eric Siemers, Yaakov Stern, Kristine Yaffe, Maria C Carrillo, Bill Thies, Marcelle Morrison-Bogorad, Molly V Wagster Show all

Alzheimer's & Dementia | ELSEVIER SCIENCE INC | Published : 2011

Abstract

The pathophysiological process of Alzheimer's disease (AD) is thought to begin many years before the diagnosis of AD dementia. This long "preclinical" phase of AD would provide a critical opportunity for therapeutic intervention; however, we need to further elucidate the link between the pathological cascade of AD and the emergence of clinical symptoms. The National Institute on Aging and the Alzheimer's Association convened an international workgroup to review the biomarker, epidemiological, and neuropsychological evidence, and to develop recommendations to determine the factors which best predict the risk of progression from "normal" cognition to mild cognitive impairment and AD dementia. ..

View full abstract

Grants

Awarded by NATIONAL INSTITUTE ON AGING


Funding Acknowledgements

Reisa Sperling has served as a site investigator and/or consultant to several companies developing imaging biomarkers and pharmacological treatments for early AD, including Avid, Bayer, Bristol-Myers-Squibb, Elan, Eisai, Janssen, Pfizer, and Wyeth. Paul Aisen serves on a scientific advisory board for NeuroPhage; serves as a consultant to Elan Corporation, Wyeth, Eisai Inc., Bristol-Myers Squibb, Eli Lilly and Company, NeuroPhage, Merck & Co., Roche, Amgen, Abbott, Pfizer Inc., Novartis, Bayer, Astellas, Dainippon, Biomarin, Solvay, Otsuka, Daiichi, AstraZeneca, Janssen, and Medivation Inc.; receives research support from Pfizer Inc. and Baxter International Inc.; and has received stock options from Medivation Inc. and NeuroPhage. Clifford Jack serves as a consultant for Eli Lilly, Eisai, and Elan; is an investigator in clinical trials sponsored by Baxter and Pfizer Inc.; and owns stock in Johnson and Johnson. Denise Park has received research support from Avid Pharmaceuticals. Eric Siemers is an employee of Eli Lilly and Company, which acquired Avid Pharmaceuticals. Yaakov Stern has consulted to Bayer Pharmaceuticals and has received research support from Bayer, Janssen, Eli Lilly, and Elan. Maria Carrillo is an employee of the Alzheimer's Association and reports no conflicts. Bill Thies is an employee of the Alzheimer's Association and reports no conflicts. Creighton Phelps is an employee of the U.S. Government and reports no conflicts.